»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀåÀº 2024-2029³â 195¾ï 3,560¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø ±â°£ µ¿¾È CAGR 22.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ Æ÷ÇÔÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº PARP ¾ïÁ¦Á¦ÀÇ Àû¿ë È®´ë, ´Ù¾çÇÑ ¾Ï ÀûÀÀÁõ¿¡ ´ëÇÑ Ä¡·áÀÇ ¿ëÀ̼º, ȯÀÚ Áö¿ø ÇÁ·Î±×·¥ÀÇ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ
2025³â
Á¾·á ¿¬µµ
2029
¿¹Ãø ±â°£
2025-2029³â
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
Àü³âºñ
18.1%
CAGR
22.5%
Áõ°¡¾×
195¾ï 3,560¸¸ ´Þ·¯
ÀÌ Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü°¡ÀÚÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ ¹× 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î °áÇÕÇÏ¿© ¼öÇàµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®, Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ªº° ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ÇâÈÄ ¸î ³â µ¿¾È PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î ÇöÀç ÁøÇà ÁßÀÎ ±¤¹üÀ§ÇÑ ¿¬±¸¸¦ ²Å°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ÏÀÇ À¯º´·ü Áõ°¡¿Í Àΰ£ À¯ÀüÀÚ¿¡ ´ëÇÑ »õ·Î¿î ¿¬±¸ ºÐ¾ß´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå Technavio ºÐ¼®
°¡°Ý¡¤¼ö¸íÁֱ⡤°í°´ ±¸ÀÔ ¹Ù½ºÄÏ¡¤Ã¤¿ë·ü¡¤±¸ÀÔ ±âÁØ ºÐ¼®
ÀÎDzÀÇ Á߿伺°ú Â÷º°È ¿äÀÎ
È¥¶õ ¿äÀÎ
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
Á¦3Àå ½ÃÀå »óȲ
½ÃÀå »ýŰè
½ÃÀå Æ¯Â¡
¹ë·ùüÀÎ ºÐ¼®
Á¦4Àå ½ÃÀå ±Ô¸ð
½ÃÀå Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð 2024³â
½ÃÀå Àü¸Á 2024-2029³â
Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû
PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ¼¼°è ½ÃÀå 2019-2023³â
À¯Åë ä³Îº° ºÎ¹® ºÐ¼® 2019-2023³â
ÃÖÁ¾»ç¿ëÀÚº° ºÎ¹® ºÐ¼® 2019-2023³â
¾à¹° Ŭ·¡½ºº° ºÎ¹® ºÐ¼® 2019-2023³â
Áö¿ªº° ºÎ¹® ºÐ¼® 2019-2023³â
±¹°¡º° ºÎ¹® ºÐ¼® 2019-2023³â
Á¦6Àå Á¤¼º ºÐ¼®
AIÀÇ ¿µÇâ : PARP(Poly ADP-Ribose Polymerase) ¾ïÁ¦Á¦ ¼¼°è ½ÃÀå
Á¦7Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
±¸¸ÅÀÚÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô Âü¿©¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀïÀÇ À§Çù
½ÃÀå »óȲ
Á¦8Àå ½ÃÀå ¼¼ºÐÈ : À¯Åë ä³Îº°
½ÃÀå ºÎ¹®
ºñ±³ : À¯Åë ä³Îº°
¼Ò¸Å ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
º´¿ø ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
¿Â¶óÀÎ ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
½ÃÀå ±âȸ : À¯Åë ä³Îº°
Á¦9Àå ½ÃÀå ¼¼ºÐÈ : ÃÖÁ¾»ç¿ëÀÚº°
½ÃÀå ºÎ¹®
ºñ±³ : ÃÖÁ¾»ç¿ëÀÚº°
³¼Ò¾Ï : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
À¯¹æ¾Ï : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
½ÃÀå ±âȸ : ÃÖÁ¾»ç¿ëÀÚº°
Á¦10Àå ½ÃÀå ¼¼ºÐÈ : ¾à¹° Á¾·ùº°
½ÃÀå ºÎ¹®
ºñ±³ : ¾à¹° Á¾·ùº°
Olaparib : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
Niraparib : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
Rucaparib : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
Talazoparib : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
½ÃÀå ±âȸ : ¾à¹° Á¾·ùº°
Á¦11Àå °í°´ »óȲ
Á¦12Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
Áö¿ªº° ºñ±³
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
¼¼°è ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
ÇÁ¶û½º : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
ÀÌÅ»¸®¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
½ºÆäÀÎ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
¸ß½ÃÄÚ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2024-2029³â
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦13Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀå °úÁ¦
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀå ±âȸ¡¤¾ïÁ¦¿äÀÎ
Á¦14Àå °æÀï ±¸µµ
°³¿ä
°æÀï ±¸µµ
È¥¶õ »óȲ
¾÷°è ¸®½ºÅ©
Á¦15Àå °æÀï ºÐ¼®
±â¾÷ °³¿ä
±â¾÷ ¼øÀ§ Áö¼ö
±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
AbbVie Inc.
Allarity Therapeutics Inc.
AstraZeneca Plc
Bayer AG
BeiGene Ltd.
Daiichi Sankyo Co. Ltd.
Everest Pharmaceuticals Ltd.
GlaxoSmithKline Plc
IMPACT Therapeutics
Jeil Pharmaceuticals Co. Ltd.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Merck and Co. Inc.
Ono Pharmaceutical Co. Ltd.
Pfizer Inc.
Zai Lab Ltd.
Á¦16Àå ºÎ·Ï
ksm
The parp (Poly ADP-Ribose Polymerase) inhibitors market is forecasted to grow by USD 19,535.6 mn during 2024-2029, accelerating at a CAGR of 22.5% during the forecast period. The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanded application of parp inhibitors, ease of administration for treatment of various cancer indications, and increasing patient assistance programs.
Market Scope
Base Year 2025
End Year 2029
Series Year 2025-2029
Growth Momentum Accelerate
YOY 2025 18.1%
CAGR 22.5%
Incremental Value $19,535.6 mn
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's parp (Poly ADP-Ribose Polymerase) inhibitors market is segmented as below:
By Distribution Channel
Retail pharmacies
Hospital pharmacies
Online pharmacies
By End-user
Ovarian cancer
Breast cancer
Others
By Drug Class
Olaparib
Niraparib
Rucaparib
Talazoparib
Others
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the extensive ongoing research as one of the prime reasons driving the parp (Poly ADP-Ribose Polymerase) inhibitors market growth during the next few years. Also, growing prevalence of cancer and new research areas in human genes will lead to sizable demand in the market.
The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market covers the following areas:
PARP (Poly ADP-Ribose Polymerase) Inhibitors Market sizing
PARP (Poly ADP-Ribose Polymerase) Inhibitors Market forecast
PARP (Poly ADP-Ribose Polymerase) Inhibitors Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-Ribose Polymerase) inhibitors market vendors that include AbbVie Inc., Allarity Therapeutics Inc., Artios Pharma, AstraZeneca Plc, Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Everest Pharmaceuticals Ltd., GlaxoSmithKline Plc, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Repare Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zai Lab Ltd.. Also, the parp (Poly ADP-Ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Distribution Channel
Executive Summary - Chart on Market Segmentation by End-user
Executive Summary - Chart on Market Segmentation by Drug Class
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitors Market 2019 - 2023
Historic Market Size - Data Table on Global PARP (Poly ADP-Ribose Polymerase) Inhibitors Market 2019 - 2023 ($ million)
5.2 Distribution Channel segment analysis 2019 - 2023
Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
5.3 End-user segment analysis 2019 - 2023
Historic Market Size - End-user Segment 2019 - 2023 ($ million)
5.4 Drug Class segment analysis 2019 - 2023
Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
5.5 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.6 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
6.1 The impact of AI in the global PARP (poly ADP-ribose polymerase) inhibitors market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Distribution Channel
8.1 Market segments
Chart on Distribution Channel - Market share 2024-2029 (%)
Data Table on Distribution Channel - Market share 2024-2029 (%)
8.2 Comparison by Distribution Channel
Chart on Comparison by Distribution Channel
Data Table on Comparison by Distribution Channel
8.3 Retail pharmacies - Market size and forecast 2024-2029
Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
8.4 Hospital pharmacies - Market size and forecast 2024-2029
Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
8.5 Online pharmacies - Market size and forecast 2024-2029
Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
8.6 Market opportunity by Distribution Channel
Market opportunity by Distribution Channel ($ million)
Data Table on Market opportunity by Distribution Channel ($ million)
9 Market Segmentation by End-user
9.1 Market segments
Chart on End-user - Market share 2024-2029 (%)
Data Table on End-user - Market share 2024-2029 (%)
9.2 Comparison by End-user
Chart on Comparison by End-user
Data Table on Comparison by End-user
9.3 Ovarian cancer - Market size and forecast 2024-2029
Chart on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
Data Table on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
Chart on Ovarian cancer - Year-over-year growth 2024-2029 (%)
Data Table on Ovarian cancer - Year-over-year growth 2024-2029 (%)
9.4 Breast cancer - Market size and forecast 2024-2029
Chart on Breast cancer - Market size and forecast 2024-2029 ($ million)
Data Table on Breast cancer - Market size and forecast 2024-2029 ($ million)
Chart on Breast cancer - Year-over-year growth 2024-2029 (%)
Data Table on Breast cancer - Year-over-year growth 2024-2029 (%)
9.5 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
9.6 Market opportunity by End-user
Market opportunity by End-user ($ million)
Data Table on Market opportunity by End-user ($ million)
10 Market Segmentation by Drug Class
10.1 Market segments
Chart on Drug Class - Market share 2024-2029 (%)
Data Table on Drug Class - Market share 2024-2029 (%)
10.2 Comparison by Drug Class
Chart on Comparison by Drug Class
Data Table on Comparison by Drug Class
10.3 Olaparib - Market size and forecast 2024-2029
Chart on Olaparib - Market size and forecast 2024-2029 ($ million)
Data Table on Olaparib - Market size and forecast 2024-2029 ($ million)
Chart on Olaparib - Year-over-year growth 2024-2029 (%)
Data Table on Olaparib - Year-over-year growth 2024-2029 (%)
10.4 Niraparib - Market size and forecast 2024-2029
Chart on Niraparib - Market size and forecast 2024-2029 ($ million)
Data Table on Niraparib - Market size and forecast 2024-2029 ($ million)
Chart on Niraparib - Year-over-year growth 2024-2029 (%)
Data Table on Niraparib - Year-over-year growth 2024-2029 (%)
10.5 Rucaparib - Market size and forecast 2024-2029
Chart on Rucaparib - Market size and forecast 2024-2029 ($ million)
Data Table on Rucaparib - Market size and forecast 2024-2029 ($ million)
Chart on Rucaparib - Year-over-year growth 2024-2029 (%)
Data Table on Rucaparib - Year-over-year growth 2024-2029 (%)
10.6 Talazoparib - Market size and forecast 2024-2029
Chart on Talazoparib - Market size and forecast 2024-2029 ($ million)
Data Table on Talazoparib - Market size and forecast 2024-2029 ($ million)
Chart on Talazoparib - Year-over-year growth 2024-2029 (%)
Data Table on Talazoparib - Year-over-year growth 2024-2029 (%)
10.7 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
10.8 Market opportunity by Drug Class
Market opportunity by Drug Class ($ million)
Data Table on Market opportunity by Drug Class ($ million)
11 Customer Landscape
11.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
12.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
12.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
12.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ million)
Data Table on North America - Market size and forecast 2024-2029 ($ million)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
12.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ million)
Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
12.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ million)
Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
12.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
12.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ million)
Data Table on US - Market size and forecast 2024-2029 ($ million)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
12.8 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ million)
Data Table on UK - Market size and forecast 2024-2029 ($ million)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
12.9 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ million)
Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
12.10 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ million)
Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
12.11 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ million)
Data Table on China - Market size and forecast 2024-2029 ($ million)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
12.12 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ million)
Data Table on France - Market size and forecast 2024-2029 ($ million)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
12.13 Italy - Market size and forecast 2024-2029
Chart on Italy - Market size and forecast 2024-2029 ($ million)
Data Table on Italy - Market size and forecast 2024-2029 ($ million)
Chart on Italy - Year-over-year growth 2024-2029 (%)
Data Table on Italy - Year-over-year growth 2024-2029 (%)
12.14 Spain - Market size and forecast 2024-2029
Chart on Spain - Market size and forecast 2024-2029 ($ million)
Data Table on Spain - Market size and forecast 2024-2029 ($ million)
Chart on Spain - Year-over-year growth 2024-2029 (%)
Data Table on Spain - Year-over-year growth 2024-2029 (%)
12.15 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ million)
Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
12.16 Mexico - Market size and forecast 2024-2029
Chart on Mexico - Market size and forecast 2024-2029 ($ million)
Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
Chart on Mexico - Year-over-year growth 2024-2029 (%)
Data Table on Mexico - Year-over-year growth 2024-2029 (%)
12.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
13 Drivers, Challenges, and Opportunity/Restraints
13.1 Market drivers
13.2 Market challenges
13.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
13.4 Market opportunities/restraints
14 Competitive Landscape
14.1 Overview
14.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
Overview on factors of disruption
14.4 Industry risks
Impact of key risks on business
15 Competitive Analysis
15.1 Companies profiled
15.2 Company ranking index
15.3 Market positioning of companies
Matrix on companies position and classification
15.4 AbbVie Inc.
AbbVie Inc. - Overview
AbbVie Inc. - Product / Service
AbbVie Inc. - Key news
AbbVie Inc. - Key offerings
SWOT
15.5 Allarity Therapeutics Inc.
Allarity Therapeutics Inc. - Overview
Allarity Therapeutics Inc. - Product / Service
Allarity Therapeutics Inc. - Key offerings
SWOT
15.6 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product / Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
SWOT
15.7 Bayer AG
Bayer AG - Overview
Bayer AG - Business segments
Bayer AG - Key news
Bayer AG - Key offerings
Bayer AG - Segment focus
SWOT
15.8 BeiGene Ltd.
BeiGene Ltd. - Overview
BeiGene Ltd. - Business segments
BeiGene Ltd. - Key offerings
BeiGene Ltd. - Segment focus
SWOT
15.9 Daiichi Sankyo Co. Ltd.
Daiichi Sankyo Co. Ltd. - Overview
Daiichi Sankyo Co. Ltd. - Product / Service
Daiichi Sankyo Co. Ltd. - Key offerings
SWOT
15.10 Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. - Overview
Everest Pharmaceuticals Ltd. - Product / Service
Everest Pharmaceuticals Ltd. - Key offerings
SWOT
15.11 GlaxoSmithKline Plc
GlaxoSmithKline Plc - Overview
GlaxoSmithKline Plc - Business segments
GlaxoSmithKline Plc - Key news
GlaxoSmithKline Plc - Key offerings
GlaxoSmithKline Plc - Segment focus
SWOT
15.12 IMPACT Therapeutics
IMPACT Therapeutics - Overview
IMPACT Therapeutics - Product / Service
IMPACT Therapeutics - Key offerings
SWOT
15.13 Jeil Pharmaceuticals Co. Ltd.
Jeil Pharmaceuticals Co. Ltd. - Overview
Jeil Pharmaceuticals Co. Ltd. - Product / Service
Jeil Pharmaceuticals Co. Ltd. - Key offerings
SWOT
15.14 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
SWOT
15.15 Merck and Co. Inc.
Merck and Co. Inc. - Overview
Merck and Co. Inc. - Business segments
Merck and Co. Inc. - Key news
Merck and Co. Inc. - Key offerings
Merck and Co. Inc. - Segment focus
SWOT
15.16 Ono Pharmaceutical Co. Ltd.
Ono Pharmaceutical Co. Ltd. - Overview
Ono Pharmaceutical Co. Ltd. - Product / Service
Ono Pharmaceutical Co. Ltd. - Key offerings
SWOT
15.17 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
SWOT
15.18 Zai Lab Ltd.
Zai Lab Ltd. - Overview
Zai Lab Ltd. - Product / Service
Zai Lab Ltd. - Key offerings
SWOT
16 Appendix
16.1 Scope of the report
16.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
16.3 Currency conversion rates for US$
Currency conversion rates for US$
16.4 Research methodology
16.5 Data procurement
16.6 Data validation
16.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
16.8 Data synthesis
16.9 360 degree market analysis
360 degree market analysis
16.10 List of abbreviations